White House, Lilly and Novo Agree to GLP-1 Price Cuts and Wider Access

Overview

• The administration said initial oral GLP-1 doses will be offered at $149 per month through Medicare, Medicaid and the TrumpRx platform if the pills receive FDA clearance.
• For currently available injectables such as Wegovy and Zepbound, Medicare and Medicaid pricing will be set at $245 per month with Medicare patient copays capped at $50.
• Officials outlined a phased rollout with cash prices taking effect by January, Medicare changes targeted for mid-2026, and Medicaid adoption proceeding as states opt in, with TrumpRx.gov planned for 2026.
• Government officials said the companies will receive tariff relief and expedited-review vouchers, and noted that commercial insurers could access prices about 25% below current cash rates.
• Novo Nordisk’s oral Wegovy is under FDA review with a decision expected late 2025, Lilly aims to file orforglipron by year-end with a possible 2026 launch, and the announcement event briefly paused when a pharmaceutical employee fainted and was later reported to be fine.